DB05633ExperimentalSmall molecule
Neuren Pharmaceuticals was developing Glypromate (glycine-proline glutamate), a naturally occurring small-molecule neuroprotectant derived from IGF-1 which inhibits caspase III dependent apoptosis, for the potential treatment of neurodegenerative diseases by IV... In December 2008, the company discontinued further development of the drug after it failed to show an observable effect.
- Mechanism
- Curator reviewed
Pharmacologically active on NMDA receptor
- Primary indication
- Investigated for use/treatment in neurologic disorders.Curator reviewed
- Formula / weight
- C12H19N3O6 · 301.299 g/mol (avg)
- Also known as
- Gly-pro-glu
Resolves to
Structure
InChIKey
JJGBXTYGTKWGAT-YUMQZZPRSA-NSMILES[H]N([H])CC(=O)N1CCC[C@H]1C(=O)N([H])[C@@H](CCC(O)=O)C(O)=OWhat you can answer from here — as of July 03, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which companies are running trials of Glypromate, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account